Eli Lilly and Company (NYSE:LLY) Given New $1,500.00 Price Target at JPMorgan Chase & Co.

Eli Lilly and Company (NYSE:LLY) had its target price hoisted by JPMorgan Chase & Co. from $1,400.00 to $1,500.00 in a research report report published on Monday, MarketBeat reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Other equities analysts also recently issued reports about the company. Cantor Fitzgerald lifted their target price on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Jefferies Financial Group increased their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, August 26th. UBS Group set a $1,376.00 price objective on shares of Eli Lilly and Company in a report on Friday, August 7th. Finally, Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,311.96.

Eli Lilly and Company Trading Up 0.2%

LLY opened at $1,185.97 on Monday. Eli Lilly and Company has a 52 week low of $716.08 and a 52 week high of $1,292.65. The business has a fifty day simple moving average of $1,177.90 and a 200-day simple moving average of $1,084.61. The firm has a market cap of $1.12 trillion, a P/E ratio of 39.80, a P/E/G ratio of 1.46 and a beta of 0.50. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company’s revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities analysts expect that Eli Lilly and Company will post 36.62 earnings per share for the current year.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 13,500 shares of company stock valued at $15,958,170. Corporate insiders own 0.14% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LLY. QRG Capital Management Inc. lifted its position in Eli Lilly and Company by 9.6% in the second quarter. QRG Capital Management Inc. now owns 146,305 shares of the company’s stock valued at $175,483,000 after acquiring an additional 12,755 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Eli Lilly and Company by 7.7% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 41,689 shares of the company’s stock valued at $49,991,000 after acquiring an additional 2,976 shares during the period. State Street Corp increased its holdings in shares of Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after acquiring an additional 605,752 shares during the period. Silicon Valley Capital Partners raised its position in Eli Lilly and Company by 3.7% in the 2nd quarter. Silicon Valley Capital Partners now owns 13,489 shares of the company’s stock valued at $16,179,000 after purchasing an additional 480 shares during the last quarter. Finally, Security National Bank of Sioux City Iowa IA purchased a new stake in Eli Lilly and Company in the 2nd quarter valued at $120,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan raised its price target to $1,500 and maintained an “overweight” rating, implying substantial upside and reinforcing confidence in Lilly’s growth outlook. Citigroup also sees the potential for approximately 35% appreciation, although it cited risks from pricing pressure and a slower oral GLP-1 launch. JPMorgan price-target article
• Positive Sentiment: FDA approval expanded Olumiant’s U.S. label to adolescents aged 12 and older with severe alopecia areata. The decision broadens the product’s addressable market beyond its existing adult indications and provides another potential revenue stream outside Lilly’s leading GLP-1 medicines. Olumiant FDA approval article
• Positive Sentiment: Momentum in Lilly’s oral GLP-1 business appears to be building. CEO David Ricks said Foundayo represents roughly one-third of new oral GLP-1 starts, while approximately 700,000 seniors reportedly began GLP-1 treatment after Medicare coverage began, with Lilly capturing about 70% of those patients. Lilly oral GLP-1 article
• Neutral Sentiment: Lilly launched the Change the Course Commitment to expand access to its diabetes and obesity medicines in low- and middle-income countries by 2040. The initiative could support long-term market expansion and public goodwill, but near-term financial benefits are uncertain and broader access could pressure pricing. Change the Course Commitment article
• Negative Sentiment: Competition in obesity drugs is intensifying. Novo Nordisk reported favorable CagriSema results in one Phase 3 comparison, while Roche’s experimental enicepatide produced significant weight loss and improved glucose control. These developments could challenge Lilly’s share and valuation over time. Novo Nordisk trial article
• Negative Sentiment: Investors continue to monitor pricing pressure, the pace of the oral GLP-1 rollout and litigation exposure, including a jury award of $90 million to Nektar. Lilly’s premium valuation makes execution and competitive risks more important to the stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.